Objective: To systematically evaluate the efficacy and safety of different drug administration routes for the treatment of premature infants with patent ductus arteriosus. Methods: PubMed

EMBase

the Cochrane Library

Wanfang

CNKI and VIP databases were retrieved from the establishment of the database to Sept. 6th

2021. Randomized controlled trial with oral administration (experimental group) and intravenous administration ( control group) for the treatment of ductus arteriosus in preterm infants was included. Meta-analysis was conducted with RevMan 5. 3 software. Results: Totally 5 articles were enrolled

including 330 patients. Meta-analysis showed that there was no significant difference in the arterial duct closure rate between the oral administration group and the intravenous administration group (RR= 1. 04

95% CI from 0. 96 to 1. 12

P = 0. 39). There was no significant difference in the incidence of related adverse drug reactions

mortality and length of stay between two groups (P>0. 05). Conclusion: Current evidence suggests that there is no significant difference in the efficacy and safety of oral versus intravenous administration for the treatment of PDA. Due to the number and quality of studies

more high-quality randomized controlled studies are still needed to explore the effects of different routes of administration on PDA closure in preterm infants with different characteristics and timing of administration.